Syntaxin Ltd. is a newly formed biotechnology company focusing on discovery and development of new medicines derived from bacterial toxins to treat chronic diseases.

The biotechnology company was created in 2005 to develop complex proteins that can be used as biopharmaceuticals to treat neurological, respiratory and endocrine diseases.

The Company's biotechnology product pipeline is based on exploiting the potent pharmacological properties of some microbial proteins, notably exotoxins.

 

Novel Recombinant Proteins

Creating Novel

Proteins

Syntaxin's engineered protein therapeutics create novel drugs.
Endocrine Disorder

Treat Endocrine

Diseases

Syntaxin are developing new treatments to tackle neuroendocrine cancer.